Navigation Links
Cantel Medical Acquires the Sterilization Monitoring Business of ConFirm Monitoring Systems, Inc.
Date:2/14/2011

LITTLE FALLS, N.J., Feb. 14, 2011 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex International subsidiary, has further expanded its infection prevention and control business by purchasing the sterilization monitoring business of ConFirm Monitoring Systems, Inc.  Based in Denver, Colorado, ConFirm is one of the leading providers of biological monitoring services in North America.  

ConFirm offers both a mail-in service and in-office spore test kits for healthcare professionals to verify the performance of their sterilizers in accordance with industry guidelines for daily or weekly testing.  With approximately $4.0 million in GAAP sales, the privately-held enterprise was founded 10 years ago and conducts over two million tests per year.  The purchase price is comprised of $7.5 million in cash at closing and contingent consideration of up to an additional $1.0 million based on achievement of specified sales levels through January 31, 2012.  The transaction is expected to be slightly accretive to Cantel's earnings per share in the first full fiscal year.

According to Gary Steinberg, CEO of Crosstex, "ConFirm is an ideal addition to our sterilization product portfolio.  Given that the sterilizer is a critical component of infection control in every dental office and most healthcare facilities, we want to provide the most effective tools to ensure it is functioning properly.  When used in conjunction with our patent-pending Sure-Check® sterilization pouch, ConFirm's biological monitoring systems enable us to provide the highest form of sterility assurance."

Andrew Krakauer, CEO of Cantel Medical added, "I am very impressed with the employees, operations, and high service-orientation of ConFirm. We are delighted that Mark Frampton will continue as the general manager for at least the first year.  Crosstex will be retaining the Denver operation and all of the aligned employees to ensure a smooth transition for all distributors and end-users.  I see this as a great opportunity to leverage the strong sales and marketing capabilities of our Crosstex platform."

About Crosstex International

A subsidiary of Cantel Medical Corp., Crosstex, founded in 1953, has its headquarters and major manufacturing operations in Hauppauge, New York. Sold throughout the world, Crosstex branded and private label products include sterilization pouches and accessories, face masks, patient towels and bibs, disinfectants, germicidal wipes, hand care products, gloves, eyewear, sponges, cotton products, scalpels and blades, sharps containers, saliva ejectors and evacuation tips.  For further information, visit the Crosstex website at http://www.crosstex.com.

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for the dental industry, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.  For further information, visit the Cantel website at http://www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.


'/>"/>
SOURCE Cantel Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cantel Medical Corp. To Hold Conference call to Discuss Fourth Quarter and Fiscal 2008 Results
2. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
3. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
4. Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions
5. Californias Biomedical Industry is Poised for Growth Despite Increasing Global Competition, According to the 2011 California Biomedical Industry Report
6. Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research
7. Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal
8. Boston Scientific Acquires Intelect Medical
9. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
10. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
11. Aethlon Medical Announces Washington, DC Shareholder Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies to join the ... Vironika, a spin out from The Wistar Institute, and Sanguis, launched by a trio ... Market Street. , Vironika is developing a treatment for a chronic viral infection ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
Breaking Biology Technology:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
Breaking Biology News(10 mins):